Fig. 1.
Effect of systemic administration of rmIL-12 on leukemia growth. SJL mice (8 to 10 mice/group) were injected IV (tail vein) with live 105 AML cells on day 0. rmIL-12 was administered SC (2.5 μg/injection) on days 0 through 4, 14 through 18, and 28 through 32 (•). Control mice (□) received injections with PBS. A solid arrow indicates the time of spleen histology and FACScan analysis. This graph is representative of 4 independent experiments.
